More man­u­fac­tur­ing is­sues: Fen­nec preps for sec­ond CRL for po­ten­tial hear­ing loss drug

Shares of Fen­nec Phar­ma­ceu­ti­cals stock were cut al­most in half ear­ly Mon­day as the com­pa­ny said man­u­fac­tur­ing is­sues caused an­oth­er FDA re­jec­tion of its re­for­mu­lat­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER